provision for incremental spending on ACTs, although not at the level of subsidy suggested in this report, which means that some portion of the estimated US$300-500 million for a global antimalarial drug subsidy should be added to the total.

REFERENCES

Coleman PG, Morel CM, Shillcutt SD, Goodman CA, Mills AJ. Forthcoming. A threshold analysis of the cost-effectiveness of artemisinin-based combination therapies in sub-Saharan Africa. American Journal of Tropical Medicine and Hygiene.

Commission on Macroeconomics and Health. 2001. Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization.

Cornille-Brogger R, Mathews HM, Storey J, Ashkar TS, Brogger S, Molineaux L. 1978. Changing patterns in the humoral immune response to malaria before, during, and after the application of control measures: A longitudinal study in the West African savanna. Bulletin of the World Health Organization 56(4):579-600.


Goodman CA, Coleman PG, Mills AJ. 2000. Economic Analysis of Malaria Control in Sub-Saharan Africa. Geneva: Global Forum for Health Research.


Laxminarayan R. Forthcoming. ACT now or later: Economics of malaria resistance. American Journal of Tropical Medicine and Hygiene.


Narasimhan V, Attaran A. 2003. Roll Back Malaria? The scarcity of international aid for malaria control. Malaria Journal 2(1):8.


Pringle G, Avery-Jones S. 1966. Observations on the early course of untreated falciparum malaria in semi-immune African children following a short period of protection . Bulletin of the World Health Organization 34(2):269-272.


WHO. 1996. Investing in Health Research and Development: Report of the Ad Hoc Committee on Health Research Relating to Future Intervention Options. TDR/Gen/96.1. Geneva: World Health Organization.

WHO. 2002. World Health Report 2002. Geneva: World Health Organization.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement